Literature DB >> 30472423

Clofazimine for the treatment of multidrug-resistant tuberculosis.

C Lange1, D Chesov2, J Heyckendorf3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30472423     DOI： 10.1016/j.cmi.2018.11.010

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


× No keyword cloud information.
  4 in total

Review 1.  Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors:  Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-05       Impact factor: 4.813

Review 2.  Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems.

Authors:  Daniélle van Staden; Richard K Haynes; Joe M Viljoen
Journal:  Antibiotics (Basel)       Date:  2022-06-15

3.  Multidrug-resistant Mycobacterium tuberculosis: a report of cosmopolitan microbial migration and an analysis of best management practices.

Authors:  Oana Joean; Thea Thiele; Katharina Schütz; Nicolaus Schwerk; Ludwig Sedlacek; Barbara Kalsdorf; Ulrich Baumann; Matthias Stoll
Journal:  BMC Infect Dis       Date:  2020-09-17       Impact factor: 3.090

Review 4.  Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field.

Authors:  Navisha Dookie; Azraa Khan; Nesri Padayatchi; Kogieleum Naidoo
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.